X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (43) 43
humans (42) 42
immunotherapy (35) 35
nivolumab (30) 30
aged (26) 26
male (26) 26
oncology (25) 25
programmed cell death 1 receptor - antagonists & inhibitors (23) 23
cancer (22) 22
melanoma (22) 22
female (19) 19
ipilimumab (18) 18
middle aged (18) 18
apoptosis (17) 17
dermatology (17) 17
antibodies, monoclonal - adverse effects (16) 16
care and treatment (16) 16
chemotherapy (14) 14
pembrolizumab (14) 14
adult (13) 13
melanoma - drug therapy (13) 13
patients (13) 13
treatment outcome (13) 13
aged, 80 and over (12) 12
antibodies, monoclonal - therapeutic use (12) 12
antineoplastic agents - adverse effects (12) 12
antineoplastic agents - therapeutic use (12) 12
case report (12) 12
metastasis (12) 12
safety (12) 12
metastatic melanoma (11) 11
skin neoplasms - drug therapy (11) 11
programmed cell death 1 receptor - immunology (10) 10
antibodies, monoclonal, humanized - adverse effects (9) 9
antibodies, monoclonal, humanized - therapeutic use (9) 9
survival (9) 9
therapy (9) 9
anti-programmed death-1 (8) 8
antibody (8) 8
expression (8) 8
immune checkpoint (8) 8
medicine, research & experimental (8) 8
open-label (8) 8
prognosis (8) 8
skin neoplasms - pathology (8) 8
anti-programmed cell death-1 (7) 7
antibodies (7) 7
antigens (7) 7
development and progression (7) 7
immunotherapy - methods (7) 7
lung cancer (7) 7
lung neoplasms - drug therapy (7) 7
retrospective studies (7) 7
tumors (7) 7
young adult (7) 7
abridged index medicus (6) 6
antineoplastic agents, immunological - therapeutic use (6) 6
cancer therapies (6) 6
cells (6) 6
drug therapy (6) 6
lung neoplasms - pathology (6) 6
lymphocytes (6) 6
melanoma - pathology (6) 6
neoplasms. tumors. oncology. including cancer and carcinogens (6) 6
research (6) 6
t cells (6) 6
usage (6) 6
advanced melanoma (5) 5
anti-pd-1 (5) 5
anti-programmed death-1 antibody (5) 5
article (5) 5
biochemistry (5) 5
cell death (5) 5
disease-free survival (5) 5
medical research (5) 5
metastases (5) 5
neoplasm staging (5) 5
nivolumab - therapeutic use (5) 5
pd-1 blockade (5) 5
programmed cell death 1 receptor - metabolism (5) 5
radiation therapy (5) 5
survival rate (5) 5
viral antibodies (5) 5
analysis (4) 4
animals (4) 4
anti-programmed cell death 1 (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antineoplastic agents (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic agents, immunological - adverse effects (4) 4
b7-h1 antigen - antagonists & inhibitors (4) 4
biomarkers (4) 4
blockade (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, renal cell - drug therapy (4) 4
carcinoma, squamous cell - drug therapy (4) 4
cell lung-cancer (4) 4
clinical trials (4) 4
ctla-4 antigen - antagonists & inhibitors (4) 4
diabetes (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Dermatology, ISSN 0385-2407, 02/2016, Volume 43, Issue 2, pp. 121 - 124
Journal Article
Journal Article
Journal Article
Medicine, ISSN 0025-7974, 01/2017, Volume 96, Issue 1, p. e5747
Introduction: In development of novel therapies for the treatment of patient with cancer, the use of radiotherapy (RT) can produce significant local control... 
Pneumonitis | Radiotherapy (RT) | Anti-programmed cell death protein 1 (PD-1) treatment | Upregulation | Programmed death-ligand 1 (PD-L1) | Immune-escape | CELLS | programmed death-ligand 1 (PD-L1) | pneumonitis | TUMOR | THYMOMA | anti-programmed cell death protein 1 (PD-1) treatment | immune-escape | radiotherapy (RT) | RADIATION-THERAPY | MEDICINE, GENERAL & INTERNAL | ANTICANCER CHEMOTHERAPY | upregulation | MICE | INNOVATIONS | ANTIGEN | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Pneumonia - etiology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lung Neoplasms - therapy | Melanoma, Amelanotic - therapy | Chemoradiotherapy | Adenocarcinoma - secondary | Melanoma, Amelanotic - secondary | Neoplasms - therapy | Adenocarcinoma - therapy | Lung Neoplasms - secondary | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Thymus Neoplasms - pathology | Thymoma - therapy | Aged | Neoplasms - pathology | Jejunal Neoplasms - pathology | Thymoma - secondary | Complications and side effects | Pneumonia | Care and treatment | Usage | Bacterial pneumonia | Dosage and administration | Diagnosis | Drug therapy, Combination | Radiotherapy | Risk factors | Cancer | Antineoplastic antibiotics
Journal Article
Muscle & Nerve, ISSN 0148-639X, 12/2017, Volume 56, Issue 6, pp. E162 - E167
ABSTRACT Introduction Pembrolizumab, a monoclonal antibody directed against the immune checkpoint programmed cell death‐1 receptor (PD‐1), has improved... 
pembrolizumab | toxic neuropathy | immune neuropathy | polyradiculoneuropathy | anti‐programmed death‐1 receptor | GUILLAIN-BARRE-SYNDROME | CNS DEMYELINATION | anti-programmed death-1 receptor | CANCER | NEUROSCIENCES | CLINICAL NEUROLOGY | THERAPY | MULTIPLE-SCLEROSIS | PATIENT | CHECKPOINT | MYASTHENIA-GRAVIS | NIVOLUMAB | IPILIMUMAB TREATMENT | Polyradiculopathy - complications | Antibodies, Monoclonal, Humanized - adverse effects | Melanoma - complications | Skin Neoplasms - drug therapy | Humans | Muscle Weakness - complications | Male | Treatment Outcome | Skin Neoplasms - complications | Antineoplastic Agents, Immunological - adverse effects | Muscle Weakness - diagnostic imaging | Melanoma - drug therapy | Muscle Weakness - chemically induced | Adult | Polyradiculopathy - diagnostic imaging | Polyradiculopathy - chemically induced | Care and treatment | Cell death | Melanoma | Monoclonal antibodies | GABA | Metastasis | Drug therapy | Cancer | Drugs | Intravenous administration | Parkinson's disease | PD-1 protein | Cerebrospinal fluid | Foaming agents | Immunosuppressive agents | Metastases | Atrophy | Fibrillation | Movement disorders | Limbs | Cell survival | Neurodegenerative diseases | Complications | Side effects | Immune checkpoint | Magnetic resonance imaging | Steroid hormones | Steroids | Apoptosis | Index Medicus
Journal Article
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 05/2018, Volume 45, Issue 5, pp. 587 - 591
Anti‐programmed cell death receptor‐1 (PD‐1) antibodies represent an effective treatment opinion for advanced melanoma and non‐small‐cell lung cancer, as well... 
immune checkpoint inhibitor | immune‐related adverse events | nivolumab | anti‐programmed death cell receptor‐1 | oral lichenoid reaction | anti-programmed death cell receptor-1 | immune-related adverse events | ANTI-PD-1 THERAPY | SAFETY | PLANUS | CANCER | DERMATOLOGY | Lung Neoplasms - drug therapy | Glucocorticoids - therapeutic use | Adenocarcinoma - pathology | Lichenoid Eruptions - drug therapy | Adenocarcinoma of Lung | Mouth - drug effects | Humans | Lichenoid Eruptions - chemically induced | Antibodies, Monoclonal - adverse effects | Ulcer - epidemiology | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Incidence | Ulcer - pathology | Antineoplastic Agents - adverse effects | Ulcer - drug therapy | Female | Skin - pathology | Administration, Oral | Treatment Outcome | Adenocarcinoma - drug therapy | Lichenoid Eruptions - pathology | Ulcer - chemically induced | Biopsy | Lichenoid Eruptions - epidemiology | Nivolumab | Mouth - pathology | Quality of Life | Aged | Administration, Topical | Skin - drug effects | Lung cancer, Non-small cell | Cell death | Ulcers | Corticoids | Tongue | Endocrine system | Lung cancer | Liver | Mucosa | Melanoma | Dermis | Gastrointestinal tract | Patients | Quality of life | Immune checkpoint | Skin | Apoptosis
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 10/2017, Volume 44, Issue 10, pp. 1156 - 1159
A 70‐year‐old woman was diagnosed with a malignant melanoma of the occipital skin which was resected; however, multiple lung metastases were detected.... 
melanoma | programmed death‐ligand 1 expression | immune‐related pneumonitis | mutation load | anti‐programmed death 1 blockade | immune-related pneumonitis | anti-programmed death 1 blockade | programmed death-ligand 1 expression | ORGANIZING PNEUMONIA | CANCER | IPILIMUMAB | DERMATOLOGY | Lung Neoplasms - drug therapy | Glucocorticoids - therapeutic use | Skin Neoplasms - drug therapy | Bone Neoplasms - therapy | Humans | Bone Neoplasms - secondary | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - pathology | Lung Diseases, Interstitial - diagnostic imaging | Ribs - diagnostic imaging | Lung Neoplasms - secondary | Muscle Neoplasms - genetics | Biomarkers, Tumor - metabolism | Female | Ribs - pathology | Bone Neoplasms - genetics | Prednisolone - therapeutic use | Skin Neoplasms - pathology | Lung - pathology | Gene Expression Profiling - methods | Muscle Neoplasms - secondary | Treatment Outcome | Melanoma - pathology | B7-H1 Antigen - genetics | Lung Diseases, Interstitial - drug therapy | Sequence Analysis, DNA | Whole Exome Sequencing | Lung Diseases, Interstitial - immunology | B7-H1 Antigen - metabolism | Melanoma - drug therapy | Aged | Biomarkers, Tumor - genetics | Polymorphism, Single Nucleotide | Muscle, Skeletal - pathology | Care and treatment | Analysis | Lung diseases | Melanoma | Muscles | Metastasis | Gene expression | Musculoskeletal system | Pneumonitis | PD-L1 protein | Skin | Patients | Prednisolone | Skeletal muscle | Metastases | Skin cancer
Journal Article
Dermatology (Actas Dermo-Sifiliográficas, English Edition), ISSN 1578-2190, 2016, Volume 108, Issue 1, pp. 6 - 16
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1803 - 1813
Journal Article